Author(s):
Mohammad Naanaa, Faten Sliman, Hala Barakat
Email(s):
muhamed.nanaa@tishreen.edu.sy. , fatensliman@tartous-univ.edu.sy. , halabarakat@tishreen.edu.sy.
DOI:
10.52711/0974-360X.2026.00295 
Address:
Mohammad Naanaa1*, Faten Sliman2, Hala Barakat3
1Master Student in Pharmaceutical Chemistry and Quality Control Department, Faculty of Pharmacy, Latakia University, Syria.
2Professor in in Pharmaceutical Chemistry and Quality Control Department, Faculty of Pharmacy, Tartous University, Syria.
3Professor in in Pharmaceutical Chemistry and Quality Control Department, Faculty of Pharmacy, Latakia, Syria
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
c-Src tyrosine kinase is a member of the SRC family kinase, it plays a critical role in various cellular processes, including proliferation, migration, and apoptosis by modulating cell signaling pathways. Dysregulation of c-Src kinase is implicated in numerous diseases, particularly cancer, where its aberrant activation promotes tumor growth, metastasis, and drug resistance. This study explored the use of Quantitative Structure-Activity Relationship (QSAR) modeling to design novel inhibitors targeting c-Src kinase. By compiling a dataset of known c-Src inhibitors, calculating descriptors, and employing multiple linear regression analysis, a robust QSAR model was developed. Key descriptors such as Jurs_PPSA1, Jx, and HBA_Count were identified as significant contributors to inhibition activity. Based on the findings from the Structure-Activity Relationship (QSAR) analysis, several new compounds have been proposed, they showed a high potency as c-SRC enzyme inhibitors.
Cite this article:
Mohammad Naanaa, Faten Sliman, Hala Barakat. QSAR Study for Developing a New c-SRC Tyrosine Kinase Inhibitors. Research Journal Pharmacy and Technology. 2026;19(5):2059-4. doi: 10.52711/0974-360X.2026.00295
Cite(Electronic):
Mohammad Naanaa, Faten Sliman, Hala Barakat. QSAR Study for Developing a New c-SRC Tyrosine Kinase Inhibitors. Research Journal Pharmacy and Technology. 2026;19(5):2059-4. doi: 10.52711/0974-360X.2026.00295 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-5-16
REFERENCES:
1. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997; 13: 513-609 doi:10.1146/annurev.cellbio.13.1.513.
2. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002; 1602(2): 114-30 doi:10.1016/s0304-419x(02)00040-9.
3. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10): 587-95 doi:10.1038/nrclinonc.2009.129.
4. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004; 4(6): 470-80 doi:10.1038/nrc1366.
5. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003; 22(4): 337-58 doi:10.1023/a:1023772912750.
6. Dubey R, Chandraker G, Sahu P, Paroha S, Sahu D, Verma S, et al. Computer aided drug design: A review. 2011; 2(3): 104-8
7. Bairagi A, Singhai AK, Jain AJAJPT. Artificial Intelligence: Future Aspects in the Pharmaceutical Industry an Overview. 2024; 14: 237-46
8. Kalkotwar R, Saudagar RJAJoPR. Design, Synthesis and anti microbial, anti-inflammatory, Antitubercular activities of some 2, 4, 5-trisubstituted imidazole derivatives. 2013; 3(4): 159-65
9. Dighe NS, Shinde P, Anap H, Bhawar S, Musmade DSJAJoPR. QSAR Study and Synthesis of some new 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives as Anti-microbial and Anti-inflammatory Agents. 2014; 4(4): 174-9
10. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014; 14(16): 1923-38 doi:10.2174/1568026614666140929124445.
11. Ganatra S, Patle M, Bhagat GJAJoRiC. Studies of Quantitative Structure-Activity Relationship (QSAR) of Hydantoin Based Active Anti-Cancer Drugs. 2011; 4(10)
12. Prema V, Sivaramakrishnan M, Rabiya M. A Concise Review on role of QSAR in Drug Design. 2023
13. Dighe AS, Tajamulhaq AEJAJoPR. An Overview of Molecular Docking. 2024; 14(3)
14. Sapkale G, Khandare D, Patil S, Surwase USJAJoRiC. Drug Design: An Emerging Era of Modern Pharmaceutical Medicines. 2010; 3(2): 261-4
15. Bhardwaj S, Dubey S. Qsar and Docking Studies of Some Novel Piperine Analogues as Monoamine Oxidase Inhibitors. 2022
16. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin, II, Cronin M, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014; 57(12): 4977-5010 doi:10.1021/jm4004285.
17. Hassan BM, Kumar GG. In silico chemistry and biology: current and future prospects/edited by Girish Kumar Gupta and Mohammad Hassan Baig.
18. Prajapati PM, Shah YR, Sen DJJRJoS, Technology. Artificial Neural Network: A New Approach for QSAR Study. 2011; 3(1): 17-24
19. Altmann E, Widler L, Missbach M. N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src. Mini Rev Med Chem. 2002; 2(3): 201-8 doi:10.2174/1389557023406188.
20. Missbach M, Altmann E, Widler L, Šuša M, Buchdunger E, Mett H, et al. Substituted 5, 7-diphenyl-pyrrolo [2, 3d] pyrimidines: potent inhibitors of the tyrosine kinase c-Src. 2000; 10(9): 945-9
21. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999; 24(5): 437-49 doi:10.1016/s8756-3282(99)00020-4.
22. Tropsha A, Gramatica P, Gombar VKJQ, Science C. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. 2003; 22(1): 69-77